ArticleThe oncologist2012

Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.

Lindsay Hedden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.